Birchview Capital LP increased its holdings in shares of DocGo Inc. (NASDAQ:DCGO - Free Report) by 48.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 764,062 shares of the company's stock after acquiring an additional 249,062 shares during the period. DocGo comprises about 2.6% of Birchview Capital LP's investment portfolio, making the stock its 10th biggest position. Birchview Capital LP owned 0.75% of DocGo worth $3,240,000 at the end of the most recent quarter.
Several other institutional investors have also made changes to their positions in the business. JPMorgan Chase & Co. lifted its holdings in DocGo by 151.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 109,855 shares of the company's stock valued at $365,000 after purchasing an additional 66,097 shares during the last quarter. Matrix Asset Advisors Inc. NY bought a new position in shares of DocGo in the fourth quarter worth about $424,000. Vanguard Group Inc. raised its stake in shares of DocGo by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 5,014,375 shares of the company's stock worth $21,261,000 after acquiring an additional 14,454 shares during the last quarter. Rhumbline Advisers raised its stake in shares of DocGo by 4.5% in the fourth quarter. Rhumbline Advisers now owns 142,762 shares of the company's stock worth $605,000 after acquiring an additional 6,204 shares during the last quarter. Finally, WCM Investment Management LLC raised its stake in shares of DocGo by 64.2% in the fourth quarter. WCM Investment Management LLC now owns 4,314,071 shares of the company's stock worth $18,637,000 after acquiring an additional 1,687,100 shares during the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.
DocGo Price Performance
NASDAQ DCGO traded down $0.04 during trading on Thursday, reaching $2.20. 484,252 shares of the company's stock were exchanged, compared to its average volume of 742,558. The business has a 50 day moving average price of $2.72 and a 200-day moving average price of $3.74. The stock has a market capitalization of $223.85 million, a P/E ratio of 7.84, a PEG ratio of 14.16 and a beta of 1.12. DocGo Inc. has a fifty-two week low of $2.02 and a fifty-two week high of $5.68.
Analyst Ratings Changes
A number of research firms have recently weighed in on DCGO. Deutsche Bank Aktiengesellschaft downgraded DocGo from a "buy" rating to a "hold" rating and cut their price target for the company from $5.00 to $2.85 in a research note on Friday, February 28th. Stifel Nicolaus reduced their target price on DocGo from $6.50 to $5.50 and set a "buy" rating on the stock in a report on Friday, February 28th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $4.00 target price on shares of DocGo in a report on Tuesday, April 8th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, DocGo presently has a consensus rating of "Moderate Buy" and a consensus price target of $4.89.
Check Out Our Latest Stock Report on DocGo
DocGo Profile
(
Free Report)
DocGo Inc provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services.
Featured Articles

Before you consider DocGo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DocGo wasn't on the list.
While DocGo currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.